Haemonetics Corporation - 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended September 29, 2001
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems, including blood bank, red cell, surgical, and plasma collection products. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 29, 2001 |
3 Months Ended Sept 30, 2000 |
6 Months Ended Sept 29, 2001 |
6 Months Ended Sept 30, 2000 |
|---|---|---|---|---|
| Net Revenues | $80,704 | $70,943 | $156,505 | $141,208 |
| Gross Profit | $39,801 | $33,421 | $76,112 | $66,867 |
| Gross Margin | 49.3% | 47.1% | 48.6% | 47.4% |
| Operating Income | $12,954 | $(14,493) | $22,486 | $(6,645) |
| Net Income | $9,948 | $(15,117) | $19,892 | $(8,893) |
| Diluted EPS | $0.37 | $(0.60) | $0.73 | $(0.35) |
| Cash from Operations (6mo) | $16,007 | $24,694 | ||
| Cash & Equivalents (End) | ||||
| Total Debt (Current + Long-term) | $80,483 (Current: $33,180; Long-term: $47,303) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 13.8% (quarterly) and 10.8% (six-month) compared to the prior year. On a constant currency basis, growth was 15.8% and 12.2%, respectively.
- Profitability Turnaround: The company reported a net income of $9.9 million for the quarter, a significant improvement from a net loss of $15.1 million in the prior year quarter. This reversal is largely attributable to the absence of significant one-time acquisition charges incurred in the prior year.
- Acquisition Charges: The prior year period included $18.6 million in In-Process Research and Development (IPR&D) charges and $4.2 million in other unusual charges related to the acquisition of Transfusion Technologies. These charges were absent in the current period.
- Product Performance:
- Disposables: Increased 13.6% (quarterly), driven by growth in Red Cell (up 45.2% constant currency), Surgical (up 15.1%), and Plasma (up 31.0%) segments.
- Equipment: Revenues surged 76.9% (quarterly) due to international sales of platelet/plasma machines and domestic sales of the new ACP 215 product.
- Working Capital: Cash from operations decreased year-over-year due to increased inventory levels ($10.7 million increase) and higher accounts receivable, offset by higher net income.
Guidance, Outlook, and Risks
- Accounting Changes: The company adopted SFAS No. 142 (Goodwill) and SFAS No. 133 (Derivatives). Goodwill is no longer amortized, improving operating income. A cumulative effect of the accounting change for derivatives resulted in a $2.3 million net charge in the six-month period.
- Product Pipeline:
- Chairside Separator (CSS): Clinical safety study completed; 510K submitted to FDA in September 2001. Sales expected upon approval (potentially one year or more).
- Red Cell Collector (RCC): Estimated at 67% completion. Sales expected in fiscal year 2004. Estimated remaining development costs are approximately $4.4 million over the next three years.
- Cost Initiatives: The "CORE" program generated approximately $1.0 million in cost savings for the quarter, with full-year savings expected from automation and vendor negotiations.
- Risks and Uncertainties:
- Foreign Exchange: Approximately 63% of revenues are generated outside the U.S. The company uses forward contracts to hedge, but currency fluctuations remain a risk.
- Regulatory: Product launches depend on FDA approvals (e.g., CSS).
- Market Conditions: Risks include the impact of the September 11, 2001 events, competitive pricing, and changes in healthcare policy.
Investor Verification Checklist
- Acquisition Impact: Verify the sustainability of operating margins excluding the one-time $22.8 million in acquisition-related charges from the prior year.
- Inventory Levels: Review the $10.7 million increase in inventory to ensure it aligns with sales forecasts and does not indicate obsolescence risk.
- Regulatory Approvals: Monitor the FDA approval timeline for the CSS product, as revenue recognition is contingent on this event.
- Foreign Currency Exposure: Assess the effectiveness of hedging strategies given that 63% of revenue is international and the volatility of the Euro and Yen.
- Debt Structure: Note that 93% of long-term debt is fixed-rate, limiting interest rate risk but maintaining a fixed obligation of approximately $80.5 million total debt.